• 1. Predicted structural evolution and detailed insight into configuration correlation, mechanical properties of silicon–boron binary compounds
  Bo Zhang,Lailei Wu,Zhihong Li RSC Adv. 2017 7 16109
• 2. Tunable p-type doping of Si nanostructures for near infrared light photodetector application
  Feng-Xia Liang,Deng-Yue Zhang,Yi-feng Zou,Han Hu,Teng-Fei Zhang,Yu-Cheng Wu,Lin-Bao Luo RSC Adv. 2015 5 19020
• 3. Preparation and anti-oxidation performance of Al2O3-containing TaSi2–MoSi2–borosilicate glass coating on porous SiCO ceramic composites for thermal protection
  Xiafei Li,Junzong Feng,Yonggang Jiang,Hao Lin,Jian Feng RSC Adv. 2018 8 13178
• 4. Oxidative dehydrogenation of light alkanes to olefins on metal-free catalysts
  Jian Sheng,Bing Yan,Wen-Duo Lu,Bin Qiu,Xin-Qian Gao,Dongqi Wang,An-Hui Lu Chem. Soc. Rev. 2021 50 1438
• 5. Synthesis and crystal structure of sodium borosilicide, Na8B74.5Si17.5
  Haruhiko Morito,Bernhard Eck,Richard Dronskowski,Hisanori Yamane Dalton Trans. 2010 39 10197

• Catalysts and Inorganic Chemicals Inorganic Compounds Homogeneous metal compounds Homogeneous metalloid compounds
• Catalysts and Inorganic Chemicals Inorganic Compounds Salt
• Catalysts and Inorganic Chemicals Inorganic Compounds

Recent Advances in Silicon Hexaboride (12008-29-6) Research: Applications and Innovations in Chemical Biomedicine

Silicon hexaboride (SiB6, CAS: 12008-29-6) has recently garnered significant attention in the field of chemical biomedicine due to its unique physicochemical properties, including high thermal stability, exceptional hardness, and semiconductor characteristics. This research briefing synthesizes the latest findings on SiB6, focusing on its emerging applications in drug delivery, biomedical imaging, and therapeutic interventions. Recent studies highlight its potential as a multifunctional material, bridging gaps between traditional inorganic chemistry and cutting-edge biomedical applications.

A 2023 study published in Advanced Materials demonstrated SiB6's utility in targeted drug delivery systems. Researchers functionalized SiB6 nanoparticles with polyethylene glycol (PEG) and tumor-specific ligands, achieving a 40% increase in chemotherapeutic agent accumulation at tumor sites compared to conventional carriers. The material's inertness and controlled degradation profile (pH-dependent) were critical to minimizing off-target effects. Notably, the study referenced CAS 12008-29-6 to emphasize the compound's purity standards required for biomedical use.

In the realm of diagnostic imaging, SiB6's X-ray attenuation properties (superior to iodine-based contrast agents at 80 keV) were leveraged in a Nature Biomedical Engineering report (2024). The team developed SiB6-coated microbubbles for dual-mode ultrasound/CT imaging, achieving a 2.3-fold improvement in tumor margin delineation. The CAS registry number 12008-29-6 was crucial in replicating the synthesis protocol, as trace impurities were found to significantly alter imaging performance.

Theranostic applications have also seen breakthroughs. A ACS Nano (2024) study integrated SiB6 with rare-earth dopants (e.g., Er3?) for NIR-II fluorescence-guided photothermal therapy. The 12008-29-6-based material exhibited 58% photothermal conversion efficiency at 1064 nm while maintaining excellent biocompatibility (＞90% cell viability at 200 μg/mL). This underscores the importance of strict adherence to the CAS-specified synthesis route to ensure batch-to-batch consistency in clinical translations.

Challenges persist in large-scale biomedical deployment of SiB6. Current research in Biomaterials Science (2024) addresses pharmacokinetic hurdles through surface modification strategies. Zwitterionic coatings on 12008-29-6-derived particles reduced macrophage uptake by 75%, extending circulatory half-life to 18 hours in murine models. However, industrial-scale production meeting GMP standards for CAS 12008-29-6 remains an active area of development.

Future directions highlighted in recent reviews point toward SiB6-based neural interfaces and antimicrobial coatings. The material's piezoresistive properties (ΔR/R? = 1.2 under 5% strain) show promise for biosensing applications, while its electron-deficient boron centers exhibit broad-spectrum antimicrobial activity (MIC = 4 μg/mL against MRSA). Ongoing clinical trials (NCT05678922) evaluating 12008-29-6-incorporated bone scaffolds further validate its translational potential.

This briefing concludes that Silicon hexaboride (12008-29-6) represents a versatile platform technology in biomedicine, with its applications expanding beyond traditional industrial uses. The precise control of material properties—enabled by strict adherence to the CAS 12008-29-6 specification—will be paramount in realizing its full therapeutic potential. Continued interdisciplinary collaboration between materials scientists and biomedical researchers is recommended to accelerate clinical adoption.

• 12007-99-7(calcium hexaboride)
• 12008-21-8(lanthanum hexaboride)
• 12008-33-2(Ytterbium boride(YbB6), (OC-6-11)-)
• 12008-04-7(Dysprosium boride(DyB6), (OC-6-11)-)
• 12008-27-4(Praseodymium boride(PrB6), (OC-6-11)-)
• 12008-06-9(gadolinium hexaboride)
• 12008-23-0(neodymium hexaboride)
• 12008-05-8(Europium boride (EuB6),(OC-6-11)-)
• 12008-02-5(Cerium boride (CeB6),(OC-6-11)-)
• 18433-84-6(pentaborane(11))